Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2006 1
2008 3
2010 2
2011 1
2012 2
2013 1
2014 1
2015 1
2017 1
2018 3
2019 5
2020 5
2021 5
2022 4
2023 6
2024 7
2025 7
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean bonsu son (1 results)?
Distinct impact of RF and ACPA titre on the effectiveness and persistency of biologics and JAK inhibitors: The ANSWER cohort study.
Etani Y, Okita Y, Maeda Y, Tsujimoto K, Hirao M, Onishi A, Onizawa H, Okano T, Nishimura K, Yoshikawa A, Shiba H, Amuro H, Son Y, Hashimoto M, Okano T, Hara R, Yamamoto W, Tachibana S, Hayashi S, Noguchi T, Kumanogoh A, Okada S, Nakata K, Ebina K. Etani Y, et al. Among authors: son y. Mod Rheumatol. 2025 Sep 2;35(5):820-829. doi: 10.1093/mr/roaf029. Mod Rheumatol. 2025. PMID: 40103318
Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study.
Watanabe R, Ebina K, Gon T, Okano T, Murata K, Murakami K, Maeda Y, Jinno S, Shirasugi I, Son Y, Amuro H, Katayama M, Hara R, Hata K, Yoshikawa A, Yamamoto W, Tachibana S, Hayashi S, Etani Y, Katsushima M, Fukumoto K, Yamada S, Hashimoto M. Watanabe R, et al. Among authors: son y. Rheumatology (Oxford). 2024 Sep 1;63(9):2418-2426. doi: 10.1093/rheumatology/keae265. Rheumatology (Oxford). 2024. PMID: 38724245
Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study.
Onishi A, Tanaka M, Fujii T, Murata K, Murakami K, Hashimoto M, Watanabe R, Nozaki Y, Ashida C, Yamamoto W, Yamada H, Sendo S, Ebina K, Makino H, Son Y, Wada Y, Hata K, Matsuda S, Morinobu A. Onishi A, et al. Among authors: son y. Arthritis Res Ther. 2025 Mar 7;27(1):52. doi: 10.1186/s13075-025-03514-x. Arthritis Res Ther. 2025. PMID: 40055759 Free PMC article.
Differential Impact of Concomitant Methotrexate and Glucocorticoids Dosages on Biologics and JAK Inhibitors: The ANSWER Cohort Study.
Ebina K, Etani Y, Okita Y, Tsujimoto K, Maeda Y, Noguchi T, Hirao M, Murata K, Fujii T, Hashimoto M, Okano T, Kotani T, Nagai K, Okano T, Shirasugi I, Hara R, Son Y, Amuro H, Katayama M, Tachibana S, Hayashi S, Yamamoto W, Kumanogoh A, Nakata K, Okada S, Onishi A. Ebina K, et al. Among authors: son y. Int J Rheum Dis. 2025 Jul;28(7):e70351. doi: 10.1111/1756-185X.70351. Int J Rheum Dis. 2025. PMID: 40589064
Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study.
Nakayama Y, Onishi A, Yamamoto W, Yoshikawa A, Shiba H, Yoshida N, Son Y, Shirasugi I, Maeda T, Katsushima M, Hashimoto M, Etani Y, Itami T, Nozaki Y, Onizawa H, Fujii T, Murakami K, Murata K, Tanaka M, Matsuda S, Morinobu A. Nakayama Y, et al. Among authors: son y. Clin Exp Med. 2024 May 10;24(1):97. doi: 10.1007/s10238-024-01360-w. Clin Exp Med. 2024. PMID: 38727756 Free PMC article.
Association of large joint involvement at the start of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors with disease activity and drug retention in patients with rheumatoid arthritis: The ANSWER cohort study.
Shirasugi I, Onishi A, Nishimura K, Yamamoto W, Murakami K, Onizawa H, Maeda Y, Ebina K, Son Y, Amuro H, Katayama M, Hara R, Nagai K, Hiramatsu Y, Hashimoto M, Okano T, Maeda T, Hayashi S, Sendo S, Jinno S, Yamamoto Y, Yamada H, Ueda Y, Saegusa J. Shirasugi I, et al. Among authors: son y. Int J Rheum Dis. 2024 Mar;27(3):e15097. doi: 10.1111/1756-185X.15097. Int J Rheum Dis. 2024. PMID: 38439176
Sustained efficacy of second-line JAK inhibitors in patients with rheumatoid arthritis: insights from the ANSWER cohort.
Tsujimoto K, Ebina K, Okamura S, Okita Y, Etani Y, Yamamoto W, Onishi A, Onizawa H, Shirasugi I, Nakano N, Kotani T, Hiramatsu Y, Hashimoto M, Okano T, Nozaki Y, Ashida C, Son Y, Tanaka A, Hara R, Okada S, Kumanogoh A. Tsujimoto K, et al. Among authors: son y. Rheumatology (Oxford). 2025 Jul 1;64(7):4207-4217. doi: 10.1093/rheumatology/keaf157. Rheumatology (Oxford). 2025. PMID: 40111839
Comparison of retention of biologics in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study.
Jinno S, Onishi A, Hattori S, Dubreuil M, Ueda Y, Nishimura K, Okano T, Yamada H, Yamamoto W, Murata K, Onizawa H, Ebina K, Maeda Y, Son Y, Amuro H, Hara R, Hata K, Shiba H, Katayama M, Watanabe R, Hashimoto M, Saegusa J. Jinno S, et al. Among authors: son y. Rheumatology (Oxford). 2025 Feb 1;64(2):509-516. doi: 10.1093/rheumatology/keae081. Rheumatology (Oxford). 2025. PMID: 38317442
Comparative effects of biological and targeted synthetic DMARDs on incident chronic kidney disease in patients with rheumatoid arthritis.
Nishimura N, Onishi A, Yamamoto W, Nagai K, Shiba H, Okita Y, Son Y, Amuro H, Okano T, Ueda Y, Hara R, Katayama M, Yamada S, Hashimoto M, Maeda Y, Onizawa H, Fujii T, Murata K, Murakami K, Tanaka M, Matsuda S, Morinobu A. Nishimura N, et al. Among authors: son y. Rheumatology (Oxford). 2025 May 1;64(5):2395-2402. doi: 10.1093/rheumatology/keae603. Rheumatology (Oxford). 2025. PMID: 39475445
55 results